Table 6.
Study | Indication | Treatment | Anesthetic | No. | Follow-up, d | Persistent TM Perforation, % |
---|---|---|---|---|---|---|
Rauch et al, 201118 | ISSNHL | 4 × methylprednisolone 40 mg/mL of over 2 weeks | Phenol | 129 | 60 | 3.9 |
Lambert et al, 201219 | Ménière’s disease | 1 × 3 or 12 mg dexamethasone in poloxamer gel | Phenol | 30 | 84 | 3.3 |
Nakagawa et al, 201420 | SSHL | 4 × 3.8 mg/mL dexamethasone over 4-7 days | Lidocaine | 58 | 112 | 15.5 |
1 × IGF-1 10 mg/mL in gelatin hydrogel | 62 | 0.0 | ||||
Lambert et al, 201621 | Ménière’s disease | 1 × 12 mg dexamethasone in poloxamer gel | Unknown | 77 | 120 | 2.7 |
Topf et al, 201722 | Ménière’s disease or ISSHNL | ≥ 1 × dexamethasone 10 mg/mL | Phenol | 192 | 90 | 1.6 |
Abbreviations: IGF-1, insulin-like growth factor 1; ISSNHL, idiopathic sudden sensorineural hearing loss; SSHL, sudden sensorineural hearing loss; TM, tympanic membrane.